Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALMB 0168

Next Previous
Drug Profile

ALMB 0168

Alternative Names: ALMB-0168

Latest Information Update: 02 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AlaMab Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action Connexin 43 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Osteosarcoma
  • Research Osteoporosis
  • No development reported Bone metastases

Most Recent Events

  • 28 May 2025 Interim safety and efficacy data from a phase I/II trial in Osteosarcoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 16 May 2024 AlaMab Therapeutics plans a phase II trial for Solid Tumors (Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV), in May 2024 (NCT06416358)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Bone metastases(In adolescents, In the elderly, Metastatic disease, In adults) in Australia (IV, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top